These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 31460249)

  • 1. Symmetric Anti-HCV Agents: Synthesis, Antiviral Properties, and Conformational Aspects of Core Scaffolds.
    Leila ARS; Mousa MHA; Frakolaki E; Vassilaki N; Bartenschlager R; Zoidis G; Abdel-Halim M; Abadi AH
    ACS Omega; 2019 Jul; 4(7):11440-11454. PubMed ID: 31460249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and Synthesis of Novel Symmetric Fluorene-2,7-Diamine Derivatives as Potent Hepatitis C Virus Inhibitors.
    Mousa MHA; Ahmed NS; Schwedtmann K; Frakolaki E; Vassilaki N; Zoidis G; Weigand JJ; Abadi AH
    Pharmaceuticals (Basel); 2021 Mar; 14(4):. PubMed ID: 33806139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and Synthesis of Novel Bis-Imidazolyl Phenyl Butadiyne Derivatives as HCV NS5A Inhibitors.
    Hamdy J; Emadeldin N; Hamed MM; Frakolaki E; Katsamakas S; Vassilaki N; Zoidis G; Hirsch AKH; Abdel-Halim M; Abadi AH
    Pharmaceuticals (Basel); 2022 May; 15(5):. PubMed ID: 35631457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from
    Sahuc ME; Sahli R; Rivière C; Pène V; Lavie M; Vandeputte A; Brodin P; Rosenberg AR; Dubuisson J; Ksouri R; Rouillé Y; Sahpaz S; Séron K
    J Virol; 2019 May; 93(10):. PubMed ID: 30842319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sulfur(vi) fluoride exchange as a key reaction for synthesizing biaryl sulfate core derivatives as potent hepatitis C virus NS5A inhibitors and their structure-activity relationship studies.
    You Y; Kim HS; Park JW; Keum G; Jang SK; Kim BM
    RSC Adv; 2018 Sep; 8(55):31803-31821. PubMed ID: 35548241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studies of the symmetric binding mode of daclatasvir and analogs using a new homology model of HCV NS5A GT-4a.
    Saad KA; Eldawy MA; Elokely KM
    J Mol Model; 2022 Dec; 29(1):25. PubMed ID: 36580076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Redesigning of the cap conformation and symmetry of the diphenylethyne core to yield highly potent pan-genotypic NS5A inhibitors with high potency and high resistance barrier.
    Abdallah M; Hamed MM; Frakolaki E; Katsamakas S; Vassilaki N; Bartenschlager R; Zoidis G; Hirsch AKH; Abdel-Halim M; Abadi AH
    Eur J Med Chem; 2022 Feb; 229():114034. PubMed ID: 34959173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of novel small molecule inhibitors against the NS3/4A protease of hepatitis C virus genotype 4a.
    El-Sayed SM; Ali MAM; El-Gendy BEM; Dandash SS; Issac Y; Saad R; Azab MM; Mohamed MR
    Curr Pharm Des; 2018; 24(37):4484-4491. PubMed ID: 30501598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Searching for synergy: Identifying optimal antiviral combination therapy using Hepatitis C virus (HCV) agents in a replicon system.
    Pomeroy JJ; Drusano GL; Rodriquez JL; Brown AN
    Antiviral Res; 2017 Oct; 146():149-152. PubMed ID: 28882564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus.
    Bilello JP; Lallos LB; McCarville JF; La Colla M; Serra I; Chapron C; Gillum JM; Pierra C; Standring DN; Seifer M
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4431-42. PubMed ID: 24867983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transient replication of a hepatitis C virus genotype 1b replicon chimera encoding NS5A-5B from genotype 3a.
    Kylefjord H; Danielsson A; Sedig S; Belda O; Wiktelius D; Vrang L; Targett-Adams P
    J Virol Methods; 2014 Jan; 195():156-63. PubMed ID: 24120570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Preexisting Hepatitis C Virus Genotype 6 NS3, NS5A, and NS5B Polymorphisms on the
    McPhee F; Ueland J; Vellucci V; Bowden S; Sievert W; Zhou N
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30718256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of immunosuppressants on direct-acting antiviral therapy is dependent on the hepatitis C virus genotype.
    Frey A; Piras-Straub K; Walker A; Timm J; Gerken G; Herzer K
    Transpl Infect Dis; 2018 Feb; 20(1):. PubMed ID: 29111569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein.
    Belda O; Targett-Adams P
    Virus Res; 2012 Dec; 170(1-2):1-14. PubMed ID: 23009750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolutionary pathways to NS5A inhibitor resistance in genotype 1 hepatitis C virus.
    Zhou S; Williford SE; McGivern DR; Burch CL; Hu F; Benzine T; Ingravallo P; Asante-Appiah E; Howe AYM; Swanstrom R; Lemon SM
    Antiviral Res; 2018 Oct; 158():45-51. PubMed ID: 30081054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Approaches to hepatitis C treatment and cure using NS5A inhibitors.
    Kohler JJ; Nettles JH; Amblard F; Hurwitz SJ; Bassit L; Stanton RA; Ehteshami M; Schinazi RF
    Infect Drug Resist; 2014; 7():41-56. PubMed ID: 24623983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct-acting antiviral treatment in adults infected with hepatitis C virus: Reactivation of hepatitis B virus coinfection as a further challenge.
    De Monte A; Courjon J; Anty R; Cua E; Naqvi A; Mondain V; Cottalorda J; Ollier L; Giordanengo V
    J Clin Virol; 2016 May; 78():27-30. PubMed ID: 26967675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance.
    Chatterji U; Garcia-Rivera JA; Baugh J; Gawlik K; Wong KA; Zhong W; Brass CA; Naoumov NV; Gallay PA
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3327-34. PubMed ID: 24687498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Self-association and conformational variation of NS5A domain 1 of hepatitis C virus.
    Beldar S; Manimekalai MSS; Cho NJ; Baek K; Grüber G; Yoon HS
    J Gen Virol; 2018 Feb; 99(2):194-208. PubMed ID: 29300159
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Ng TI; Krishnan P; Pilot-Matias T; Kati W; Schnell G; Beyer J; Reisch T; Lu L; Dekhtyar T; Irvin M; Tripathi R; Maring C; Randolph JT; Wagner R; Collins C
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28193664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.